IP Verse

Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes - EP3294333

The patent EP3294333 was granted to Biontech Cell&Gene Therapies on Jul 9, 2025. The application was originally filed on May 9, 2016 under application number EP16721176A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3294333

BIONTECH CELL&GENE THERAPIES
Application Number
EP16721176A
Filing Date
May 9, 2016
Status
Patent Maintained As Amended
Feb 14, 2025
Grant Date
Jul 9, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR H ULRICH DORRIESMay 31, 2021DORRIESADMISSIBLE
DR H ULRICH DORRIESMay 31, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2003118592
DESCRIPTIONUS2003133939
DESCRIPTIONWO9633265
DESCRIPTIONWO9724447
INTERNATIONAL-SEARCH-REPORTWO2005113587
INTERNATIONAL-SEARCH-REPORTWO2008145338
INTERNATIONAL-SEARCH-REPORTWO2012038055
INTERNATIONAL-SEARCH-REPORTWO2014146672
OPPOSITIONEP2016060337W-
OPPOSITIONEP3126381
OPPOSITIONWO2005113587
OPPOSITIONWO2012038055
OPPOSITIONWO2014146672

Non-Patent Literature (NPL) Citations (94) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADAMS, S. ET AL., J. IMMUNOL., (2008), vol. 181, pages 776 - 784-
DESCRIPTION- ALTMAN ET AL., SCIENCE, (1996), vol. 274, pages 94 - 96-
DESCRIPTION- ATANACKOVIC, D. ET AL., J. IMMUNOL., (2004), vol. 172, pages 3289 - 3296-
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426-
DESCRIPTION- BRITTEN, C.M. ET AL., J. IMMUNOL. METHODS, (2002), vol. 259, pages 95 - 110-
DESCRIPTION- CHAUX, P. ET AL., J. IMMUNOL., (1999), vol. 163, pages 2928 - 2936-
DESCRIPTION- CHEEVER ET AL., IMMUNOLOGICAL REVIEWS, (1997), vol. 157, page 177-
DESCRIPTION- CHEN, Q. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2004), vol. 101, pages 9363 - 9368-
DESCRIPTION- CONNEROTTE, T. ET AL., CANCER RES., (2008), vol. 68, pages 3931 - 3940-
DESCRIPTION- COOPER, L.J. ET AL., J. VIROL., (2000), vol. 74, pages 8207 - 8212-
DESCRIPTION- CURIGLIANO, G. ET AL., ANN. ONCOL., (2006), vol. 17, pages 750 - 762-
DESCRIPTION- DAVIS, I.D. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2004), vol. 101, pages 10697 - 10702-
DESCRIPTION- DEMBIC, Z. ET AL., NATURE, (1986), vol. 320, pages 232 - 238-
DESCRIPTION- DUDLEY, M.E. ET AL., J. CLIN. ONCOL., (2005), vol. 23, pages 2346 - 2357-
DESCRIPTION- DUDLEY, M.E. ET AL., J. IMMUNOTHER., (2001), vol. 24, pages 363 - 373-
DESCRIPTION- DUNBAR ET AL., CURR. BIOL., (1998), vol. 8, pages 413 - 416-
DESCRIPTION- FUJIO, K. ET AL., J. IMMUNOL., (2000), vol. 165, pages 528 - 532-
DESCRIPTION- HELFTENBEIN, G. ET AL., GENE, (2008), vol. 414, pages 76 - 84-
DESCRIPTION- HOLTKAMP, S. ET AL., BLOOD, (2006), vol. 108, pages 4009 - 4017-
DESCRIPTION- HOMBACH A, GENE THERAPY, (2010), vol. 17, pages 1206 - 1213-
DESCRIPTION- HUNT, D.F. ET AL., SCIENCE, (1992), vol. 256, pages 1817 - 1820-
DESCRIPTION- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883-
DESCRIPTION- JAGER, E., PROC. NATL. ACAD. SCI. U. S. A, (2000), vol. 97, pages 12198 - 12203-
DESCRIPTION- JOHNSON, L.A. ET AL., BLOOD, (2009), vol. 114, pages 535 - 546-
DESCRIPTION- KARANJAWALA ZE ET AL., AM J SURG PATHOL, (2008), vol. 32, pages 188 - 96-
DESCRIPTION- KERSHAW M.H. ET AL., NATURE REVIEWS CANCER, (2013), vol. 13, no. 8, pages 525 - 41-
DESCRIPTION- KESSELS ET AL., NAT IMMUNOL., (2001), vol. 2, pages 957 - 61-
DESCRIPTION- KESSELS, H.W. ET AL., NAT. IMMUNOL., (2001), vol. 2, pages 957 - 961-
DESCRIPTION- KOFLER D.M. ET AL., MOLECULAR THERAPY, (2011), vol. 19, no. 4, pages 760 - 767-
DESCRIPTION- KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495-
DESCRIPTION- KREITER ET AL., CANCER IMMUNOL. IMMUNOTHER., CII, (2007), vol. 56, pages 1577 - 87-
DESCRIPTION- KREITER S. ET AL., CANCER RESEARCH, (2010), vol. 70, pages 9031 - 40-
DESCRIPTION- KREITER, S. ET AL., J. IMMUNOL., (2008), vol. 180, pages 309 - 318-
DESCRIPTION- LOZZIO, C.B.; LOZZIO, B.B, BLOOD, (1975), vol. 45, pages 321 - 334-
DESCRIPTION- MAHVI ET AL., IMMUNOLOGY AND CELL BIOLOGY, (1997), vol. 75, pages 456 - 460-
DESCRIPTION- MALOY ET AL., PROC NATL ACAD SCI USA, (2001), vol. 98, pages 3299 - 303-
DESCRIPTION- MARCHAND, M. ET AL., INT. J. CANCER, (1999), vol. 80, pages 219 - 230-
DESCRIPTION- MATZ, M. ET AL., NUCLEIC ACIDS RES., (1999), vol. 27, pages 1558 - 1560-
DESCRIPTION- MORGAN, R.A. ET AL., J. IMMUNOL., (2003), vol. 171, pages 3287 - 3295-
DESCRIPTION- MORGAN, R.A. ET AL., SCIENCE, (2006), vol. 314, pages 126 - 129-
DESCRIPTION- MULE, J.J. ET AL., SCIENCE, (1984), vol. 225, pages 1487 - 1489-
DESCRIPTION- NEDDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443-
DESCRIPTION- NIIMI T, MOLCELLBIOL, (2001), vol. 21, pages 7380 - 90-
DESCRIPTION- NOVELLINO, L. ET AL., CANCER IMMUNOL. IMMUNOTHER., (2005), vol. 54, pages 187 - 207-
DESCRIPTION- OSSENDORP ET AL., IMMUNOL LETT., (2000), vol. 74, pages 75 - 9-
DESCRIPTION- OSSENDORP ET AL., J. EXP. MED., (1998), vol. 187, pages 693 - 702-
DESCRIPTION- PAJOT A. ET AL., EUR. J. IMMUNOL., (2004), vol. 34, pages 3060 - 69-
DESCRIPTION- PEARSON; LIPMAN, PROC. NATL ACAD. SCI. USA, (1988), vol. 85, page 2444-
DESCRIPTION- PEGGS, K.S. ET AL., LANCET, (2003), vol. 362, pages 1375 - 1377-
DESCRIPTION- RAMMENSEE H. ET AL., IMMUNOGENETICS, (1999), vol. 50, pages 213 - 9-
DESCRIPTION- RIDDELL, S.R., SCIENCE, (1992), vol. 257, pages 238 - 241-
DESCRIPTION- ROONEY, C.M. ET AL., BLOOD, (1998), vol. 92, pages 1549 - 1555-
DESCRIPTION- ROSENBERG, S.A. ET AL., J. NATL. CANCER INST., (1994), vol. 86, pages 1159 - 1166-
DESCRIPTION- ROSENBERG, S.A. ET AL., NAT. MED., (2004), vol. 10, pages 909 - 915-
DESCRIPTION- ROSENBERG, S.A. ET AL., N. ENGL. J. MED., (1985), vol. 313, pages 1485 - 1492-
DESCRIPTION- ROSSI ET AL., AM. J. CLIN. PATHOL., (2005), vol. 124, page 295-
DESCRIPTION- SAHIN U ET AL., CLIN CANCER RES, (2008), vol. 14, pages 7624 - 34-
DESCRIPTION- SAHIN, U. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (1995), vol. 92, pages 11810 - 11813-
DESCRIPTION- SCANLAN, M.J. ET AL., CANCER IMMUN., (2004), vol. 4, page 1-
DESCRIPTION- SCANLAN, M.J. ET AL., IMMUNOL. REV., (2002), vol. 188, pages 22 - 32-
DESCRIPTION- SCATCHARD ET AL., ANN N.Y. ACAD. SCL, (1949), vol. 51, page 660-
DESCRIPTION- SCHMITT, M. ET AL., BLOOD ILL, (2008), pages 1357 - 1365-
DESCRIPTION- SCHULER-THURNER, B. ET AL., J. IMMUNOL., (2000), vol. 165, pages 3492 - 3496-
DESCRIPTION- SHEN, X. ET AL., J. IMMUNOTHER., (2007), vol. 30, pages 123 - 129-
DESCRIPTION- SMITH; WATERMAN, ADS APP. MATH., (1981), vol. 2, page 482-
DESCRIPTION- SPEISER, D.E. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2008), vol. 105, pages 3849 - 3854-
DESCRIPTION- SPIEKER-POLET ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1995), vol. 92, page 9348-
DESCRIPTION- STANISLAWSKI ET AL., NAT IMMUNOL., (2001), vol. 2, pages 962 - 70-
DESCRIPTION- TSUKITA S, NAT REV MOL CELL BIOL, (2001), vol. 2, pages 285 - 93-
DESCRIPTION- VAN DER BRUGGEN, P. ET AL., SCIENCE, (1991), vol. 254, pages 1643 - 1647-
DESCRIPTION- WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546-
DESCRIPTION- YEE, C. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2002), vol. 99, pages 16168 - 16173-
DESCRIPTION- ZHANG, Y. ET AL., TISSUE ANTIGENS, (2002), vol. 60, pages 365 - 371-
DESCRIPTION- ZHAO, Y. ET AL., J. IMMUNOL., (2005), vol. 174, pages 4415 - 4423-
INTERNATIONAL-SEARCH-REPORT- SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324 [XD] 1,4-9 * abstract; pages 7624-7626, 7629, 7633; Figure 1 * [A] 2,3,10-43
INTERNATIONAL-SEARCH-REPORT- M. SADELAIN ET AL, "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, (20130401), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, ISSN 2159-8274, pages 388 - 398, XP055133523 [A] 1-43 * abstract; Figures 1 and 2; Table 1; pages 388, 389, 392 *
INTERNATIONAL-SEARCH-REPORT- HUAN SHI ET AL, "Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, (20140921), vol. 13, no. 1, doi:10.1186/1476-4598-13-219, ISSN 1476-4598, page 219, XP021197368 [A] 1-43 * abstract; pages 219-222; Figure 1 *
OPPOSITION- AACR Cancer Res 2014; 74(19 Suppl), Abstract no. 2903-
OPPOSITION- Excerpt from Alberts, Bruce et al. “Molecular Biology of the Cell”-
OPPOSITION- Excerpt of the European Nucleotide Archive, sequence AB332393,created January 16, 2008 and last updated January 19, 2008-
OPPOSITION- "Homo Sapiens CLDN18 gene for claudin-18A2, promoter and partial cds.", Nucleotide, (20080116), Database accession no. AB332393, URL: NCBI, XP055814076-
OPPOSITION- Karanjawala et al., Am J Surg Pathol. 32(2): 188-196, 2008-
OPPOSITION- OEZLEM, Tuereci, et al., "IMAB362, a novel first-in-class monoclonal antibody for treatment of pancreatic cancer", AACR Cancer Research, (20140000), vol. 74, no. 19 Suppl, XP055814119-
OPPOSITION- Preliminary Opinion of the OD in EP 3126381-
OPPOSITION- Result of the oral opposition proceedings in EP 3126381-
OPPOSITION- SADELAIN M; Brentjens R; Riviere I, "The Basic Principles of Chimeric Antigen Receptor Design", Cancer Discovery, (20130000), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, pages 388 - 398-
OPPOSITION- Sahin et al., Clin Cancer Res 14(23): 7624-7634, 2008-
OPPOSITION- SHI Huan, Meili Sun; Lin Liu; Zhehai Wang, "Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects", Molecular Cancer, (20140000), vol. 13, no. 219, doi:10.1186/1476-4598-13-219-
OPPOSITION- Summons to attend oral proceedings of the opposed patent, dated February 11, 2020-
OPPOSITION- WOISA for PCT/EP2016/060337, dated November 14, 2017-
OPPOSITION- KARANJAWALA Zarir E; Illei Peter B; Ashfaq Raheela; Infante Jeffrey R; Murphy Kathleen; Pandey Akhilesh; Schulick Richard; Winter Jordan; Sharma Rajni; Maitra Anirban; Goggins Michael; Hruban Ralph H, "New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and annexin A8", Am J Surg Pathol., (20080000), vol. 32, no. 2, doi:10.1097/PAS.0b013e31815701f3, pages 188 - 196, XP009173572
OPPOSITION- SAHIN Ugur, Michael Koslowski; Karl Dhaene; Dirk Usener; Gunda Brandenburg; Gerhard Seitz; Christoph Huber; Özlem Türeci, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", Clin Cancer Res, (20080000), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, pages 7624 - 7634, XP002588324
OPPOSITION- SADELAIN M; Brentjens R; Riviere I, "The Basic Principles of Chimeric Antigen Receptor Design", Cancer Discovery, (20130000), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, pages 388 - 398, XP055133523
OPPOSITION- SHI Huan, Meili Sun; Lin Liu; Zhehai Wang, "Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects", Molecular Cancer, (20140000), vol. 13, no. 219, doi:10.1186/1476-4598-13-219, XP021197368

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents